Skip to main content

Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life

Abstract

Background

Clostridioides difficile infection (CDI) is associated with high recurrence rates impacting health-related quality of life (HrQOL). However, patient-reported data are lacking particularly in the outpatient setting. We assessed changes in HrQOL over time in patients treated with bezlotoxumab at US infusion centers and determined clinical factors associated with HrQOL changes.

Methods

The HrQOL survey was conducted in adult patients with CDI, who received bezlotoxumab in 25 US outpatient infusion centers. The survey was adapted from the Cdiff32 instrument to assess anxiety-related changes to HrQOL and completed on the day of infusion (baseline) and at 90 days post bezlotoxumab (follow-up). Demographics, disease history, CDI risk factors, and recurrence of CDI (rCDI) at 90-day follow-up were collected. Changes in HrQOL scores were calculated and outcomes assessed using a multivariable linear regression model with P < 0.05 defined as statistically significant.

Results

A total of 144 patients (mean age: 68 ± 15 years, 63% female, median Charlson index: 4, 15.9% rCDI) were included. The overall mean baseline and follow-up HrQOL scores were 26.4 ± 11.5 and 56.4 ± 25.0, respectively. At follow-up, this score was significantly higher for patients who had primary CDI (34.5 ± 21.7) compared to those with multiple rCDI (24.7 ± 21.0; P = 0.039). The mean HrQOL change at follow-up was significantly higher for patients without rCDI (34.1 ± 28.8 increase) compared to patients with rCDI (6.7 ± 19.5 increase; P < 0.001), indicating improvement in anxiety.

Conclusions

Using the Cdiff32 instrument, we demonstrated that HrQOL worsened significantly in patients with further rCDI. These findings support the use of Cdiff32 in assessing CDI-related humanistic outcomes.

Background

Clostridioides difficile (C. difficile), also known as Clostridium difficile, is the most common cause of infectious diarrhea in hospitalized patients in the United States (US) [1, 2]. In addition to its negative impact on morbidity and mortality, CDI has been associated with a long-term decline to patients’ health-related quality of life (HrQOL) [3,4,5,6,7]. Studies using quality of life instruments in CDI patients include the Short Form 36-item Health Survey, version 2 (SF-36v2®) [4], the European Quality of life-5 Dimensions-3 Levels of severity (EQ-5D-3L) [5, 6], and the European Quality of life-Visual Analogue Scale (EQ-VAS) [6]. These studies have demonstrated lower HrQOL in CDI patients compared to non-CDI patients. Another study including active and past CDI patients utilized an adapted qualitative survey and reported the majority of participants found their daily activities were impacted, particularly those with active CDI [7].

The C. difficile quality of life survey (Cdiff32) was developed to quantify disease-specific changes to HrQOL in patients with CDI [3]. This survey consists of 32 questions, including three domains and five sub-domains, designed to assess CDI-related changes to the physical, mental, and social status of CDI patients. During the development and validation of Cdiff32, the authors determined that the anxiety sub-domain, which is part of the mental domain, was significantly different in patients with primary CDI compared to patients with recurrent CDI (rCDI) [3]. The 2017 Clinical Practice Guidelines for CDI published by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) have recognized patient-reported outcomes as an important endpoint in clinical research [8]. However, no disease-specific changes to HrQOL over time in patients with CDI have been reported. We used an adapted Cdiff32 instrument to assess HrQOL over time in patients who received bezlotoxumab for prevention of rCDI in outpatient infusion centers. Previously, we reported the use of bezlotoxumab in infusion centers, which provided an opportunity to investigate HrQOL in patients with confirmed CDI [9].

The objective of this study was to assess anxiety-related HrQOL changes in patients with and without rCDI after receiving a one-time infusion of bezlotoxumab in outpatient infusion centers. We examined clinical factors associated with HrQOL changes. Study findings may help support the use of Cdiff32 in assessing impact of new CDI therapeutics on HrQOL changes in CDI patients and increase awareness of HrQOL associated with rCDI.

Methods

Study design and data collection

This was a retrospective observational analysis of patient-reported HrQOL data obtained between September 2017 and December 2020 from participating US outpatient infusion centers. Adult patients were included in the study if they received bezlotoxumab and completed the HrQOL survey on the day of bezlotoxumab infusion and again ≥ 90 days post infusion. Completion of both HrQOL surveys was standard procedure for patients receiving a single dose of bezlotoxumab (10 mg/kg) in the outpatient infusion center. Patients were required to have a confirmed positive C. difficile test and receive standard of care antibiotic therapy at the time of bezlotoxumab. Baseline demographics, Charlson comorbidity index, prior CDI episodes, CDI risk factors, and rCDI ≥ 90 days post bezlotoxumab were collected from electronic healthcare records. Recurrent CDI was defined as diarrhea lasting ≥ 2 days and resulting in medical intervention with or without a positive stool test for toxigenic C. difficile. This study was approved by an institutional review board (IntegReview IRB, Austin, TX, USA).

Survey instrument

An adapted Cdiff32 survey was used to assess patient-reported HrQOL [3]. In order to construct a survey that could be completed during the patient visit, we included one question from the general physical sub-domain regarding disruption of daily activities and six questions from the anxiety sub-domain. The survey was administered at two different time points and patients ranked their responses on a scale from 1 to 5, with 1 being the least and 5 being the most (Table 1). Patients completed the questionnaire immediately prior to receiving bezlotoxumab (baseline) and again at ≥ 90 days post bezlotoxumab during a follow-up visit or telephone interview (follow-up). Data gathered were de-identified and kept confidential. Response scores were inverted to a scale from 0 (worst HrQOL) to 100 (best HrQOL) using an equal weighting. Changes in HrQOL scores were obtained by subtracting the baseline score from the follow-up score for each patient. A positive value indicated improved HrQOL from baseline.

Table 1 Clostridioides difficile quality of life survey

Statistical analysis

Continuous data were reported as mean and standard deviation (SD) or median and interquartile range (IQR). Categorical data were analyzed as counts and percentages or frequencies. Differences in anxiety-related HrQOL scores in patients who did or did not experience rCDI following bezlotoxumab were stratified by number of CDI episodes and other potentially confounding variables using the Student’s t-test. A forward selection, multivariable linear regression model was built to assess changes in HrQOL scores over time controlling for all other clinical variables. Any variable with a P value less than 0.05 was considered statistically significant and retained in the model. Statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC) and IBM SPSS statistics version 22 (IBM, Armonk, NY).

Results

Patient characteristics

Overall, 144 patients from 25 outpatient infusion centers were included. Demographics, CDI disease characteristics, and changes in HrQOL scores from baseline to follow-up are shown in Table 2. Mean age was 68 ± 15 years and 63% of patients were female. Median Charlson index was 4 [IQR 3–6]. Prior to receiving bezlotoxumab, 24 patients (16.7%) had primary CDI, 35 (24.3%) had one recurrence, 44 (30.6%) had 2 recurrences, and 41 (28.5%) had ≥ 3 CDI recurrences. Distribution of rCDI risk factors included patients ≥ 65 years of age (n = 100, 69.4%), ≥ 1 CDI episode in previous 6 months (n = 112, 77.9%), immunocompromised (n = 53, 36.8%), current CDI with severe presentation (n = 31, 21.5%), use of gastric acid suppressants (n = 46, 31.9%), inflammatory bowel disease (n = 12, 8.3%), chronic renal disease (n = 12, 8.3%), and prior failed fecal microbiota transplant (n = 17, 11.8%). At follow-up, 23 patients (15.9%) experienced rCDI within 90 days post bezlotoxumab.

Table 2 Changes in health-related quality of life (HrQOL) scores at baseline and follow-up

Changes in HrQOL scores from baseline to follow-up

The overall HrQOL score averaged 26.4 ± 11.5 at baseline (Table 2). Patients with primary CDI had significantly higher HrQOL scores (34.5 ± 17.1) compared to patients with multiple CDI recurrences (24.7 ± 10.5; P = 0.039). However, no differences were observed between baseline HrQOL scores of patients with one CDI recurrence (22.4 ± 8.7) compared to patients with 2 (26.9 ± 12.1) or ≥ 3 CDI recurrences (24.3 ± 10.3). At follow-up, HrQOL scores averaged 56.4 ± 25.0, corresponding to a 2.1-fold increase from baseline score indicating overall improved anxiety-related HrQOL. The mean change in HrQOL score was significantly higher for patients without further rCDI (34.1 ± 28.8 HrQOL increase) compared to patients with rCDI (6.7 ± 19.5 HrQOL increase; P < 0.001). Using multivariable analysis, recurrence of CDI post bezlotoxumab (-27.4 ± 6.2 relative change in HrQOL; P < 0.0001) and chronic renal failure (− 19.7 ± 8.7 relative change in HrQOL; P = 0.025) were significantly associated with reduced changes in HrQOL compared to baseline (− 27.3 ± 6.2 relative change in HrQOL; P < 0.0001) (Table 3).

Table 3 Univariable and multivariable analyses of changes in health-related quality of life (HrQOL)

Discussion

Policy makers and clinical practice guidelines recognize patient-reported outcomes as important endpoints in clinical research and practice [8]. Consequently, health-related quality of life (HrQOL) measures seem particularly important in patients with CDI [3, 5, 10]. There are different generic tools created for patient-reported outcomes [11] and quality of life [4,5,6,7], however, Cdiff32 is the only instrument specifically developed to assess HrQOL in patients with CDI [3]. A recently conducted real-world experience study of bezlotoxumab in outpatient infusion centers [9] provided an opportunity to assess CDI patient-reported quality of life changes from baseline to follow-up using an adapted Cdiff32 survey. Our findings indicate that patients with primary CDI had significantly higher HrQOL scores at baseline indicating less anxiety compared to patients with multiple prior CDI recurrences. At follow-up, anxiety-related HrQOL worsened significantly in patients with further rCDI regardless of baseline number of CDI episodes, whereas HrQOL improved in patients without rCDI. The findings of HrQOL worsening in patients with further rCDI was confirmed by multivariable analysis.

The strength of this study includes a sizeable cohort as this is the second largest study to date demonstrating quantitative changes of patient-reported HrQOL in CDI [3,4,5,6, 10]. In addition, the current study had rigorous individual patient follow-up providing HrQOL data at two different time points. Prospective changes in anxiety-related HrQOL with further episodes of rCDI also suggest this humanistic outcome is important and should be incorporated into future intervention studies designed to prevent rCDI.

Our findings are consistent with previous reports showing decreased HrQOL in patients with CDI recurrences. Han et al. demonstrated low quality of life scores for patients hospitalized with CDI using the Cdiff32 and PROMIS Global Health surveys (10). The Cdiff32 survey was particularly sensitive to HrQOL changes in patients with recurrent and/or severe disease. Others have used various instruments to quantify quality of life in CDI patients [4,5,6,7]. Barbut et al. demonstrated the impact of the infection on patients’ quality of life using the EQ-5D-3L and EQ-VAS instruments, which showed an association between HrQOL and CDI severity [6]. Similar results were observed using the EQ-5D-3L questionnaire in patients who were hospitalized with CDI [5]. A multinational study used SF-36v2 to compare the impact of CDI on quality of life and work productivity in patients with current or prior CDI and patients without rCDI [4]. A Canadian study highlighted the long-lasting effect and emotional impact on patients with CDI [12]. All studies have consistently shown decreased HrQOL scores in patients with rCDI, with prevention of rCDI expected to improve HrQOL. The current study findings add to the understanding of the burden associated with CDI and underscore the long-lasting nature of this infectious disease.

The study has limitations. For ease of survey completion, a limited number of questions from the Cdiff32 instrument were used including one question from the general physical sub-domain and six questions from the anxiety sub-domain. Although we were able to demonstrate significant differences between recurrent and non-recurrent CDI patients using this subset of HrQOL questions, future validation of the adapted Cdiff32 survey will be required. This real-world cohort consisted of an older population of CDI patients receiving bezlotoxumab in the outpatient setting. Changes to HrQOL in younger patients and those receiving other treatments will require further research. Nevertheless, the prospective changes of HrQOL scores observed in patients with rCDI suggest that reducing the likelihood of further CDI episodes will likely improve HrQOL. Providing clinically meaningful thresholds that define improvement in HrQOL for patients with CDI should be a focus for future research.

Conclusions

HrQOL measures are particularly important in patients with CDI,

Availability of data and materials

The data that support the findings of this study are not publicly available.

Abbreviations

C. difficile :

Clostridioides difficile

CDI:

Clostridioides difficile Infection

Cdiff32:

C. difficile Quality of Life Survey

EQ-5D-3L:

European Quality of life-5 Dimensions-3 Levels of severity

EQ-VAS:

European Quality of life-Visual Analogue Scale

HrQOL:

Health-related quality of life

IDSA:

Infectious Diseases Society of America

IRB:

Institutional Review Board

rCDI:

Recurrent Clostridioides difficile infection

SF-36v2:

Short Form 36-item Health Survey, version 2

SHEA:

Society for Healthcare Epidemiology of America

US:

United States

References

  1. Desai K, Gupta SB, Dubberke ER, Prabhu VS, Browne C, Mast TC (2016) Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect Dis 16:303

    Article  Google Scholar 

  2. Guh AY, Winston LG, Johnston H et al (2020) Trends in U.S. burden of Clostridioides difficile infection and outcomes. N Engl J Med 382:1320–1330

    CAS  Article  Google Scholar 

  3. Garey KW, Aitken SL, Gschwind L et al (2016) Development and validation of a Clostridium difficile health-related quality-of-life questionnaire. J Clin Gastroenterol 50(8):631–637

    Article  Google Scholar 

  4. Heinrich K, Harnett J, Vietri J, Chambers R, Yu H, Zilberberg M (2018) Impaired quality of life, work, and activities among adults with Clostridioides difficile infection: a multinational survey. Dig Dis Sci 63(11):2864–2873

    Article  Google Scholar 

  5. Wilcox MH, Ahir H, Coia JE et al (2017) Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. J Antimicrob Chemother 72(9):2647–2656

    CAS  Article  Google Scholar 

  6. Barbut F, Galperine T, Vanhems P et al (2019) Quality of life and utility decrement associated with Clostridium difficile infection in a French hospital setting. Health Qual Life Outcomes 17(1):6

    Article  Google Scholar 

  7. Lurienne L, Bandinelli PA, Galvain T, Coursel CA, Oneto C, Feuerstadt P (2020) Perception of quality of life in people experiencing or having experienced a Clostridium difficile infection: a US population survey. J Patient-Reported Outcomes. https://doi.org/10.1186/s41687-020-0179-1

    Article  Google Scholar 

  8. McDonald LC, Gerding DN, Johnson S et al (2018) Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 66(7):e1-148

    CAS  Article  Google Scholar 

  9. Hengel RL, Ritter TE, Nathan RV et al (2020) Real-world experience of bezlotoxumab for prevention of Clostridioides difficile infection: a retrospective multicenter cohort study. In: Open forum infectious diseases, 7(4): ofaa097

  10. Han Z, Lapin B, Garey KW, Donskey CJ, Deshpande A (2021) Impact of Clostridioides difficile infection on patient-reported quality of life. Infect Control Hosp Epidemiol. https://doi.org/10.1017/ice.2021.413

    Article  PubMed  Google Scholar 

  11. Talbot GH, Kleinman L, Davies E et al (2019) Clostridioides difficile infection-daily symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder threseholds. Health Qual Life Outcomes 17:77

    Article  Google Scholar 

  12. Vent-Schmidt J, Attara GP, Lisko D, Steiner TS (2020) Patient experiences with Clostridioides difficile infection: results of a Canada-wide survey. Patient Prefer Adherence 14:33–43

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study was funded by a research grant from Merck Sharp & Dohme Corp. (Grant No. VEAP 6789), a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Author information

Authors and Affiliations

Authors

Contributions

RLH, CPS, TER, RVN, ENO, RJD, LVA and KWG contributed to the study conception and design. RLH, CPS, TER, RVN and LVA performed acquisition of data. All authors contributed to analysis and interpretation of the data. CPS, JJ, AJGL, ENO, LVA and KWG contributed to the drafting of the manuscript. CPS, ENO, LVA and KWG have contributed to critical revisions. All authors read and approved the final manuscript.

Author information

KWG is a Professor at the University of Houston College of Pharmacy and is responsible for development of the Cdiff32 instrument.

Corresponding author

Correspondence to Richard L. Hengel.

Ethics declarations

Ethics approval and consent to participate

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by an independent institutional review board and granted exemption for requiring patient consent (IntegReview IRB, Austin, TX, US).

Consent for publication

Not applicable.

Competing interests

TER is on the advisory boards for Ferring Pharmaceuticals and Rebiotix, Inc. ENO and RJD are current employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. and may own stock and/or stock options in Merck & Co., Inc., Kenilworth, NJ, USA. LVA has received research support from Merck Sharp & Dohme Corp. and is on the advisory board for Ferring Pharmaceuticals. KWG has received research support from Acrux, Summit Pharmaceuticals and is a consultant to Seres Health and Ferring Pharmaceuticals. RLH, CPS, JJ, RVN and AJGL have no potential conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hengel, R.L., Schroeder, C.P., Jo, J. et al. Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life. J Patient Rep Outcomes 6, 49 (2022). https://doi.org/10.1186/s41687-022-00456-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s41687-022-00456-9

Keywords

  • Clostridioides difficile infection
  • Quality of life
  • Recurrence